Widespread Use of High-dose Ceftriaxone Therapy for Uncomplicated Gonorrhea Without Reported Ceftriaxone Treatment Failure: Results From 5 Years of Multicenter Surveillance Data in China

Author:

Han Yan12,Yin Yueping12,Dai Xiuqin12,Chen Shaochun12,Yang Ligang34,Zhu Bangyong5,Zhong Na6,Cao Wenling7,Zhang Xiaohui34,Wu Zhizhou8,Yuan Liufeng9,Zheng Zhongjie10,Feng Lishan8,Liu Jun11,Chen Xiangsheng12

Affiliation:

1. Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College

2. National Center for Sexually Transmitted Disease (STD) Control, Chinese Center for Disease Control and Prevention, Nanjing

3. Dermatology Hospital, Southern Medical University

4. Guangdong Provincial Dermatology Hospital, Guangzhou

5. Institute of Dermatology, Guangxi Autonomous Region, Nanning

6. Hainan Provincial Center for STD/Skin Disease Control and Prevention, Haikou

7. Guangzhou Institute of Dermatology

8. Jiangmen Dermatology Hospital

9. Beijing Ditan Hospital Capital Medical University

10. Tianjin Center for Disease Control and Prevention, China

11. Massachusetts General Hospital, Harvard Medical School, Boston

Abstract

Abstract Background Antimicrobial resistance to Neisseria gonorrhoeae has emerged for each of the antibiotics recommended as first-line therapies following their introduction into clinical practice. To improve rational and effective clinical antibiotic treatment, we analyzed the prescription patterns of antibiotics and their therapeutic effect in the treatment of uncomplicated gonorrhea in China. Methods We obtained data from a follow-up multicenter surveillance program. Multinomial logistic regression analyses were conducted to explore the associations between demographic/clinical variables with the levels of sensitivity to ceftriaxone and prescription of high-dose ceftriaxone. Results In this study, 1686 patients infected with N. gonorrhoeae were recruited in a surveillance network during 1 January 2013 through 31 December 2017 in 7 hospitals distributed in 5 provinces. The prevalence of isolates with decreased susceptibility to ceftriaxone was 9.8% (131/1333), fluctuating between 5.6% and 12.1%. Injectable ceftriaxone was chosen as the first-line treatment among 83.1% of patients, and most of them (72.7% [1018/1401]) received >1000 mg dosage. Patients who were previously infected with gonorrhea or other sexually transmitted infections (adjusted odds ratio [AOR], 1.618 [95% confidence interval {CI}, 1.11–2.358]; AOR, 2.08 [95% CI, 1.41–3.069]) or who already used antibiotics for this infection (AOR, 1.599 [95% CI, 1.041–2.454]) were associated with a higher prescribed ceftriaxone dosage. All of the patients recruited in this study were cured regardless of the isolates’ susceptibility to ceftriaxone or the dosage of ceftriaxone they received. Conclusions No ceftriaxone treatment failure for uncomplicated gonorrhea was reported in China; however, high-dose ceftriaxone was widely used in China. Its impacts need further study.

Funder

Chinese Academy of Medical Sciences Initiative for Innovative Medicine

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference32 articles.

1. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates: United States, 2000–2010;Centers for Disease Control and Prevention.;MMWR Morb Mortal Wkly Rep,2011

2. Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016;Yin;PLoS Med,2018

3. Threat to cefixime treatment for gonorrhea;Yokoi;Emerg Infect Dis,2007

4. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone;Ohnishi;Antimicrob Agents Chemother,2011

5. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011;Unemo;Euro Surveill,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3